Genetically engineered placental mucosalassociated invariant T (MAIT) cells and uses thereof
AssigneePluri Biotech Ltd.
InventorsArthur Machlenkin, Adi Sharbi-Yunger, Eliran Ish Shalom, Helena Lea Shaked
Life of this patent
Estimating the term…
Abstract
This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Claims24
A cell composition comprising a population of selected placental mucosal-associated invariant T (MAIT) cells engineered to express an exogenous chimeric antigen receptor (CAR), wherein said selected placental MAIT cells are derived from intervillous blood of placental tissue, and wherein said cell composition comprises at least 109 viable engineered placental MAIT cells, wherein at least 90% of said viable engineered placental MAIT cells express TCRVα7.2+, and wherein at least 30% of said selected placental MAIT cells exhibit a CD45RA−/CD62L− effector memory phenotype.
A cell composition comprising a population of selected placental mucosal-associated invariant T (MAIT) cells engineered to express an exogenous chimeric antigen receptor (CAR), wherein said selected placental MAIT cells are derived from intervillous blood of placental tissue, and wherein said cell composition comprises at least 109 viable engineered placental MAIT cells, wherein at least 90% of said viable engineered placental MAIT cells express TCRVα7.2″, and wherein at least 70% of said selected placental MAIT cells are capable of expressing TNFα following stimulation with PMA and Ionomycin.
Dependencies are inferred from the claim text.